Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pieris
Biotech
Pieris lays off 70% of staff after AstraZeneca axes collab
Pieris is laying off 70% and putting the rest of its wholly-owned assets up for sale after AstraZeneca stepped away from a licensing pact.
Max Bayer
Jul 18, 2023 10:33am
AstraZeneca stops trials of asthma drug after seeing tox signal
Jun 21, 2023 9:10am
Pieris puts phase 2 cancer drug out on chopping block
Aug 4, 2022 4:15pm
Pieris Pharma nabs $20M upfront in Genentech collaboration
May 25, 2021 10:55am
Pieris, Seattle pen $1.2B I-O biobucks pact
Feb 9, 2018 7:16am
Daiichi cuts 6 meds in last quarter, including Pieris candidate
May 11, 2017 6:12am
